Calciphylaxis and the cardiometabolic syndrome: the emerging role of sodium thiosulfate as a novel treatment option.
Hayden
Melvin R
MR
Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65020, USA. mrh29@usmo.com
D000975:Antioxidants / Q000627:therapeutic use*; D001158:Arteries / Q000473:pathology / Q000503:physiopathology; D002115:Calciphylaxis / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000150:complications* / Q000503:physiopathology; D006435:Renal Dialysis; D013885:Thiosulfates / Q000627:therapeutic use*; D014652:Vascular Diseases / Q000150:complications / Q000473:pathology / Q000503:physiopathology
D000975:Antioxidants; D013885:Thiosulfates; C017717:sodium thiosulfate